Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc.

Dr. Reddy's Laboratories Limited RDY reported second-quarter fiscal 2026 earnings of 19 cents per American Depositary Share (ADS), which beat the Zacks Consensus Estimate of 18 cents. The company reported earnings of 17 cents per ADS in the year-ago quarter.
Revenues grew 9.8% year over year to $992 million, surpassing the Zacks Consensus Estimate of $983 million. The year-over-year improvement was primarily driven by growth in global generics revenues.
RDY’s Q2 Results in Detail
Dr. Reddy’s reported revenues under three segments — Global Generics, Pharmaceutical Services & Active Ingredients (PSAI) and Others.
Global Generics revenues totaled INR 78.5 billion, up 10% year over year. The increase was primarily driven by revenues from the acquired Nicotine Replacement Therapy portfolio in the Europe segment and sustained performance in RDY’s branded markets.
Dr. Reddy’s launched seven new products in North America during the reported quarter. However, revenues in the North America segment declined 13% primarily due to increased price erosion in certain key products, including Lenalidomide, partly offset by favorable forex and contribution from new product launches.
As of Sept. 30, 2025, a total of 75 generic filings were pending approval from the FDA, comprising 73 abbreviated new drug applications (ANDAs) and two new drug applications. Of these 73 ANDAs, 45 are Para IVs.
Shares of Dr. Reddy’s have lost 7.6% year to date against the industry’s 0.6% growth.
Image Source: Zacks Investment Research
PSAI revenues amounted to INR 9.5 billion, up 12% year over year. The improvement was driven by the launch of new active pharmaceutical ingredients (APIs) and favorable forex. Growth in the pharmaceutical services business also contributed to the year-over-year increase.
Revenues in the Others segment totaled INR 0.1 billion, down 42% on a year-over-year basis.
Gross margin declined 492 basis points to 54.7% in the second quarter of fiscal 2026 due to higher price erosion in generics and reduced operating leverage.
Research and development (R&D) expenses of $70 million were down 15% year over year as investments in biosimilars tapered following the completion of major funding for the Abatacept biosimilar candidate. R&D spending instead focused on complex generics, biosimilars, APIs and novel biologics, particularly in oncology, peptides, and injectables.
Selling, general and administrative expenses totaled $298 million, up 15% year over year. The rise was primarily driven by increased sales and marketing investments aimed at enhancing existing brands and supporting new consumer healthcare initiatives.
Key Update From RDY
Last month, Dr. Reddy’s announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for AVT03 (denosumab), a proposed biosimilar to Amgen’s AMGN Prolia and Xgeva. The opinion will now be reviewed by the European Commission, which will make the final decision on marketing authorization across the European Economic Area, including the EU, Norway, Iceland, and Liechtenstein. A separate submission to the regulatory body in the United Kingdom is also planned.
The development of AVT03 stems from a 2024 partnership between Dr. Reddy’s and Alvotech ALVO, under which Alvotech is responsible for development and manufacturing, while Dr. Reddy’s handles regulatory and commercialization activities in key markets. Dr. Reddy’s holds exclusive commercialization rights in the United States and semi-exclusive rights in Europe and the United Kingdom. Once approved, the biosimilar will be marketed as Acvybra (60 mg/mL) and Xbonzy (70 mg/mL). Earlier this year, RDY and ALVO also announced the FDA’s acceptance of a regulatory filing seeking approval of AVT03 in the United States for review. AVT03 is a human monoclonal antibody developed by Alvotech.
Amgen's Prolia treats osteoporosis in postmenopausal women at high risk of fractures, especially when other treatments are ineffective. AMGN’s Xgeva helps prevent fractures, spinal cord compression and the need for bone-related surgery or radiation in patients with multiple myeloma or bone metastases from solid tumors.
RDY and ALVO also have a partnership agreement to co-develop and commercialize a biosimilar candidate to Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), across the world. Per the agreement, RDY and ALVO will jointly share all costs for developing and manufacturing the biosimilar candidate to MRK’s Keytruda, which is approved for treating several types of cancer indications. Each company will hold the right to commercialize the product globally upon successful development.
Dr. Reddy's Laboratories Ltd Price, Consensus and EPS Surprise
Keytruda, Merck’s biggest revenue driver, generated sales worth $29.5 billion in 2024. Sales of the drug grew 6.6% year over year to $15.1 billion in the first half of 2025. Keytruda has played an instrumental role in driving Merck’s steady revenue growth in the past few years.
In September, Dr. Reddy’s signed an agreement to acquire the Stugeron portfolio from Johnson & Johnson, marking its entry into the anti-vertigo market. The deal includes the flagship Stugeron brand and its variants across 18 markets in APAC and EMEA, with India and Vietnam as key focus areas. Stugeron, a leading cinnarizine brand for vertigo treatment, enhances Dr. Reddy’s central nervous system portfolio and expands its presence in a growing therapeutic segment.
RDY's Zacks Rank
Dr. Reddy’s carries a Zacks Rank #3 (Hold) at present.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See "2nd Wave" AI stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues

For Immediate Release
Chicago, IL – October 24, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. AMZN, Wells Fargo & Co. WFC, Amgen Inc. AMGN, IDT Corp. IDT and Village Super Market, Inc. VLGEA.
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Amazon, Wells Fargo and Amgen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Wells Fargo & Co. and Amgen Inc., as well as two micro-cap stocks IDT Corp. and Village Super Market, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-markets Mostly Lower on Biggest Earnings Day of the Week
Today's Featured Research Reports
Amazon.com's shares have outperformed the Zacks Internet - Commerce industry over the past year (+18.1% vs. +17.6%). The company's top-line is driven by steady momentum in Prime and AWS. Strengthening AWS services portfolio and its growing adoption rate is contributing well to AWS performance. Ultrafast delivery services and expanding content portfolio are beneficial.
Strengthening relationships with third-party sellers is a positive. Robust advertising business is also contributing well. Growing capabilities in grocery, pharmacy, healthcare and autonomous driving are other positives. Deepening focus on GenAI is a major plus.
The Zacks analyst expect 2025 net sales to grow 10.6% from 2024. However, weak third-quarter operating income guidance of $15.5-20.5 billion and concerns about margin pressure from heavy AI investments totaling $100+ billion in capital expenditure plans are overhangs. Elevated operating expenses amid intensifying cloud competition remain headwinds.
(You can read the full research report on Amazon.com here >>>)
Shares of Wells Fargo have gained +33.5% over the past year against the Zacks Financial - Investment Bank industry's gain of +36.2%. The company's third-quarter 2025 results benefited from an improvement in net interest income (NII), fee income and lower provisions. Its earnings surpassed the estimates in each of the trailing four quarters.
The Fed's June 2025 removal of the $1.95 trillion asset cap allows growth in deposits, loans and fee-based services. After clearing the 2025 Fed stress test, Wells Fargo raised its dividend, backed by strong liquidity and capital position. Also, strategic investments in talent and technology support long-term growth.
Yet despite the recent Fed rate cut, NII recovery may remain slow, pressuring near-term revenue growth. The mortgage banking income remains weak amid ongoing mortgage rate volatility. Also, rising technology and compensation costs may weigh on profitability.
(You can read the full research report on Wells Fargo here >>>)
Amgen's shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date period (+15.4% vs. +11.1%). The company's key medicines like Evenity, Repatha and Blincyto and newer medicines like Tavneos and Tezspire, are driving sales, more than offsetting declining revenues from oncology biosimilars and mature products like Enbrel.
New biosimilar launches are also contributing to growth. Amgen has some key pipeline assets with a focus on the obesity candidate, MariTide. Data from studies on MariTide are expected in the fourth quarter. However, increased pricing headwinds and competitive pressure are hurting sales of many products.
Weakness in some key brands like Otezla and Lumakras creates potential revenue strains. Sales of best-selling drugs Prolia and Xgeva are expected to decline from the second half of 2025 due to biosimilar competition. Estimates have declined ahead of Q3 results. Amgen has a positive record of earnings surprises in recent quarters.
(You can read the full research report on Amgen here >>>)
Shares of IDT have gained +6.5% over the past year against the Zacks Diversified Communication Services industry's gain of +10.2%. This microcap company with a market capitalization of $1.25 billion has scalable, high-margin platforms — NRS, BOSS Money and net2phone — which drive sustained EBITDA and cash flow growth. NRS recurring revenues rose 27% with expanding margins and POS growth, positioning for deeper monetization via digital coupons.
BOSS Money's digital pivot lifted EBITDA, aided by margin expansion and WhatsApp integration. net2phone's AI rollout supports 54% EBITDA growth and rising ARPU. Core communications remain a cash engine funding growth. Strong liquidity ($253.8 million, no debt) and a 43% EBITDA increase underpin flexible capital returns.
Risks include working-capital drag, customer concentration, pricing elasticity and rising CapEx intensity. The valuation suggests investors can access strong earnings growth and cash generation at a discounted entry point, offering significant multiple expansion potential.
(You can read the full research report on IDT here >>>)
Village Super Market's shares have gained +15.4% over the past year against the Zacks Retail - Supermarkets industry's gain of +30.1%. This microcap company with market capitalization of $488.08 million delivered strong FY25 results, with 12% net income growth to $56.4 million, driven by 2.1% same-store sales gains, digital adoption, and pharmacy strength.
Operating margin held firm at 23.95% due to labor and occupancy efficiencies. Strategic store replacements — like the larger-format Watchung and Old Bridge locations — boosted productivity and fulfillment. FY26 includes another replacement store in East Orange. A healthy balance sheet with $110.7 million in cash and reduced debt offers financial flexibility. Dividends remain consistent and sustainable, with a low payout ratio (<25%).
Village's mix of urban and suburban formats enables targeted customer engagement. Risks include legal disputes with Wakefern, internal cannibalization, labor contract expirations, cybersecurity dependence, and margin pressures from inflation. Shares trade at 0.18x EV/sales vs. 1.22x for peers.
(You can read the full research report on Village Super Market here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks Names #1 Semiconductor Stock
This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amazon.com, Inc. (AMZN) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Zacks Analyst Blog Highlights Amazon.com, Wells Fargo, Amgen, IDT and Village Super Market

Thursday, October 23, 2025
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Wells Fargo & Co. (WFC) and Amgen Inc. (AMGN), as well as two micro-cap stocks IDT Corp. (IDT) and Village Super Market, Inc. (VLGEA). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-markets Mostly Lower on Biggest Earnings Day of the Week
Today's Featured Research Reports
Amazon.com’s shares have outperformed the Zacks Internet - Commerce industry over the past year (+18.1% vs. +17.6%). The company’s top-line is driven by steady momentum in Prime and AWS. Strengthening AWS services portfolio and its growing adoption rate is contributing well to AWS performance. Ultrafast delivery services and expanding content portfolio are beneficial.
Strengthening relationships with third-party sellers is a positive. Robust advertising business is also contributing well. Growing capabilities in grocery, pharmacy, healthcare and autonomous driving are other positives. Deepening focus on GenAI is a major plus.
The Zacks analyst expect 2025 net sales to grow 10.6% from 2024. However, weak third-quarter operating income guidance of $15.5-20.5 billion and concerns about margin pressure from heavy AI investments totaling $100+ billion in capital expenditure plans are overhangs. Elevated operating expenses amid intensifying cloud competition remain headwinds.
(You can read the full research report on Amazon.com here >>>)
Shares of Wells Fargo have gained +33.5% over the past year against the Zacks Financial - Investment Bank industry’s gain of +36.2%. The company’s third-quarter 2025 results benefited from an improvement in net interest income (NII), fee income and lower provisions. Its earnings surpassed the estimates in each of the trailing four quarters.
The Fed's June 2025 removal of the $1.95 trillion asset cap allows growth in deposits, loans and fee-based services. After clearing the 2025 Fed stress test, Wells Fargo raised its dividend, backed by strong liquidity and capital position. Also, strategic investments in talent and technology support long-term growth.
Yet despite the recent Fed rate cut, NII recovery may remain slow, pressuring near-term revenue growth. The mortgage banking income remains weak amid ongoing mortgage rate volatility. Also, rising technology and compensation costs may weigh on profitability.
(You can read the full research report on Wells Fargo here >>>)
Amgen’s shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date period (+15.4% vs. +11.1%). The company’s key medicines like Evenity, Repatha and Blincyto and newer medicines like Tavneos and Tezspire, are driving sales, more than offsetting declining revenues from oncology biosimilars and mature products like Enbrel.
New biosimilar launches are also contributing to growth. Amgen has some key pipeline assets with a focus on the obesity candidate, MariTide. Data from studies on MariTide are expected in the fourth quarter. However, increased pricing headwinds and competitive pressure are hurting sales of many products.
Weakness in some key brands like Otezla and Lumakras creates potential revenue strains. Sales of best-selling drugs Prolia and Xgeva are expected to decline from the second half of 2025 due to biosimilar competition. Estimates have declined ahead of Q3 results. Amgen has a positive record of earnings surprises in recent quarters.
(You can read the full research report on Amgen here >>>)
Shares of IDT have gained +6.5% over the past year against the Zacks Diversified Communication Services industry’s gain of +10.2%. This microcap company with a market capitalization of $1.25 billion has scalable, high-margin platforms — NRS, BOSS Money and net2phone — which drive sustained EBITDA and cash flow growth. NRS recurring revenues rose 27% with expanding margins and POS growth, positioning for deeper monetization via digital coupons.
BOSS Money’s digital pivot lifted EBITDA, aided by margin expansion and WhatsApp integration. net2phone’s AI rollout supports 54% EBITDA growth and rising ARPU. Core communications remain a cash engine funding growth. Strong liquidity ($253.8 million, no debt) and a 43% EBITDA increase underpin flexible capital returns.
Risks include working-capital drag, customer concentration, pricing elasticity and rising CapEx intensity. The valuation suggests investors can access strong earnings growth and cash generation at a discounted entry point, offering significant multiple expansion potential.
(You can read the full research report on IDT here >>>)
Village Super Market’s shares have gained +15.4% over the past year against the Zacks Retail - Supermarkets industry’s gain of +30.1%. This microcap company with market capitalization of $488.08 million delivered strong FY25 results, with 12% net income growth to $56.4 million, driven by 2.1% same-store sales gains, digital adoption, and pharmacy strength.
Operating margin held firm at 23.95% due to labor and occupancy efficiencies. Strategic store replacements — like the larger-format Watchung and Old Bridge locations — boosted productivity and fulfillment. FY26 includes another replacement store in East Orange. A healthy balance sheet with $110.7 million in cash and reduced debt offers financial flexibility. Dividends remain consistent and sustainable, with a low payout ratio (<25%).
Village’s mix of urban and suburban formats enables targeted customer engagement. Risks include legal disputes with Wakefern, internal cannibalization, labor contract expirations, cybersecurity dependence, and margin pressures from inflation. Shares trade at 0.18x EV/sales vs. 1.22x for peers.
(You can read the full research report on Village Super Market here >>>)
Other noteworthy reports we are featuring today include RTX Corp. (RTX), Marsh & McLennan Companies, Inc. (MMC) and América Móvil, S.A.B. de C.V. (AMX).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Featured Reports
Defense Orders Drive RTX Corporation (RTX), Despite Supply Chain Woes
Per the Zacks analyst, RTX is likely to benefit from increasing defense order growth from the Pentagon and US allies. Yet supply chain issues result in delays and increase costs.
Marsh & McLennan (MMC) Strategic Buyouts Aid, Expenses High
Per the Zacks analyst, multiple acquisitions help Marsh & McLennan expand geographically and diversify its portfolio. However, escalating expenses remain a concern.
Smucker (SJM) to Continue Gaining from Coffee Business Strength
Per the Zacks analyst, Smucker is likely to gain from strength in its coffee business, thanks to Folgers and Cafe Bustelo brands. In first quarter, coffee unit sales grew 15% driven by solid pricing.
AI Tax Assist Benefits H&R Block (HRB) Amid Low Liquidity
Per the Zacks Analyst, integration of a generative AI-powered technology, AI Tax Assist, in H&R Block's DIY tax preparation boosts top line. Low liquidity is concerning.
Spec Home Strategy Benefits Meritage Homes (MTH) Amid Macro Risks
Per the Zacks analyst, Meritage Homes is gaining from its speculative homebuilding strategy and land investments. However, housing market weakness and high costs are a hindrance.
R&D Focus & MedTech Strength Aid Integer Holdings (ITGR), Amid Risks
Per the Zacks analyst, Integer Holdings' strong R&D focus and solid presence in the MedTech space drive optimism. However, heavy regulation, competition, and supplier dependence remain concerns.
Global Reach & Inverter Shipments Aid SolarEdge Technologies (SEDG)
Per the Zacks analyst, SolarEdge Technologies benefits from its expanding production facilities and increased global footprint. Consistent inverter shipments will boost its performance.
New Upgrades
America Movil (AMX) Gains from Rising Subscriber Engagement
Per the Zacks analyst, America Movil's performance is benefiting from an uptick in broadband client base and wireless subscribers. An augmented 5G footprint is a tailwind.
Strong Adoption of Automated Solutions Aids Teradyne's (TER) Prospects
Per the Zacks analyst, Teradyne benefits from strong adoption of automated solutions that is automating semiconductor customers' back-end processes.
Alkermes (ALKS) Rides on Robust Sales Performance of Proprietary Drugs
Per the Zacks analyst, Alkermes' top line is being driven by the sales of its proprietary drugs, Vivitrol, Aristada and Lybalvi. The company is also making good progress with its pipeline development.
New Downgrades
Liberty Energy (LBRT) Hurt by Slowdown in Industry's Frac Activity
The Zacks analyst highlights challenges for Liberty Energy's earnings growth due to slowdown in industry's frac activity including market pricing pressures.
North American Slowdown to Pressure Halliburton (HAL)
The Zacks analyst believes that reduced spending and a cautious stance by North American operators could pressure Halliburton's onshore activity and pricing.
Subdued Truck Market & Tariffs Woes to Dent PACCAR's (PCAR) Margins
Weak truck deliveries, tariff costs, and input inflation are likely to pressure PACCAR's near-term margins amid a sluggish freight recovery, making the Zacks analyst bearish on the stock.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Research Reports for Amazon.com, Wells Fargo & Amgen

(RTTNews) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). The indication targets individuals who have not adequately responded to standard treatments, including systemic corticosteroids and/or surgery.
CRSwNP affects approximately 320 million people worldwide and is a complex disease characterised by epithelial-driven inflammation and benign polyp growths within the nasal cavity. People living with CRSwNP commonly experience airflow obstruction and symptoms including congestion and an impaired sense of smell.
Tezspire was recently approved in the US for the add-on maintenance treatment of adult and paediatric patients aged 12 years and older with inadequately controlled CRSwNP and regulatory applications are currently under review in China, Japan and several other countries. Tezspire is also approved for severe asthma in the US, EU, Japan and more than 60 countries across the globe.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $267.9 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 250,465,324 to 252,315,324). Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.8%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 2.8%, and Amgen Inc (Symbol: AMGN) is lower by about 1.3%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $127.35 per share, with $151.39 as the 52 week high point — that compares with a last trade of $144.99. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
BDCs Hedge Funds Are Selling
PNFP Historical Stock Prices
TTP Insider Buying
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy ETF Inflows: XLV, ABT, TMO, AMGN

On its third-quarterearnings conference callon Oct. 14, Johnson & Johnson JNJ discussed its preliminary outlook for 2026. J&J said that the consensus estimates for 2026, for both the top and the bottom lines, are too low.
In 2026, J&J expects top-line growth of more than 5% while the consensus estimate is around 4.6%. EPS growth is expected to be similar to revenue growth. J&J expects adjusted EPS to be around 5 cents more than the consensus of $11.39 per share. The Zacks Consensus Estimate for 2026 revenue growth is 4.8% while the same for EPS is pegged at $11.46 per share.
J&J expects growth in both the Innovative Medicine and MedTech segments to accelerate in 2026.
In 2026, J&J expects accelerated growth in the Innovative Medicine segment despite the loss of exclusivity (“LOE”) of blockbuster drug, Stelara. Several biosimilar versions of J&J’s multi-billion-dollar immunology drug, Stelara, have been launched in the United States in 2025.
According to patent settlements and license agreements, Amgen AMGN, Teva Pharmaceutical Industries TEVA, Samsung Bioepis/Sandoz and some other companies have already launched Stelara biosimilars this year. Stelara’s LOE negatively impacted the Innovative Medicines segment growth by 1070 basis points in the second quarter.
In the first nine months of 2025, Innovative Medicine Unit’s sales rose 4.5% on an operational basis to $44.64 billion.
Innovative Medicine Unit’s growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato and Erleada, as well as new drugs like Carvykti, Tecvayli and Talvey. Recently launched products, including Tremfya in inflammatory bowel disease (IBD), Rybrevant plus Lazcluze in non-small cell lung cancer and the newly approved drug, Inlexzo in bladder cancer, are also expected to contribute.
In the MedTech segment, J&J expects better growth than 2025 levels, driven by increased adoption of newly launched products across all MedTech platforms and increased focus on higher-growth markets. J&J expects to launch products like Shockwave C2 Aero catheter and Tecnis intraocular lens in the United States, as well as make a regulatory submission for the OTTAVA robotic surgical system in 2026. These new products may also contribute to growth in 2026.
In the first nine months of 2025, MedTech’s sales rose 5.3% on an operational basis to $25.0 billion.
J&J’s 2026 guidance signals more than optimism—it highlights a deliberate pivot toward innovation-led growth in both segments. With a strong pipeline and robust product launches, J&J seems prepared to deliver beyond the Street’s current expectations.
JNJ’s Price Performance, Valuation and Estimates
J&J’s shares have outperformed the industry year to date. The stock has risen 34.0% in the year-to-date period compared with a 5.1% increase in the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 17.08 forward earnings, higher than 15.52 for the industry. The stock is also trading above its five-year mean of 15.64.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has remained unchanged at $10.86 per share, while that for 2026 has risen from $11.38 to $11.46 over the past seven days.
Image Source: Zacks Investment Research
J&J has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Johnson & Johnson Targets Accelerated Growth Across Segments in 2026

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Amgen Inc (Symbol: AMGN), where a total volume of 12,526 contracts has been traded thus far today, a contract volume which is representative of approximately 1.3 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 52.7% of AMGN's average daily trading volume over the past month, of 2.4 million shares. Particularly high volume was seen for the $305 strike call option expiring October 24, 2025, with 3,429 contracts trading so far today, representing approximately 342,900 underlying shares of AMGN. Below is a chart showing AMGN's trailing twelve month trading history, with the $305 strike highlighted in orange:
Intuitive Surgical Inc (Symbol: ISRG) saw options trading volume of 11,763 contracts, representing approximately 1.2 million underlying shares or approximately 52.6% of ISRG's average daily trading volume over the past month, of 2.2 million shares. Particularly high volume was seen for the $500 strike call option expiring June 18, 2026, with 515 contracts trading so far today, representing approximately 51,500 underlying shares of ISRG. Below is a chart showing ISRG's trailing twelve month trading history, with the $500 strike highlighted in orange:
And Exelixis Inc (Symbol: EXEL) options are showing a volume of 11,370 contracts thus far today. That number of contracts represents approximately 1.1 million underlying shares, working out to a sizeable 52.5% of EXEL's average daily trading volume over the past month, of 2.2 million shares. Particularly high volume was seen for the $45 strike call option expiring November 21, 2025, with 4,097 contracts trading so far today, representing approximately 409,700 underlying shares of EXEL. Below is a chart showing EXEL's trailing twelve month trading history, with the $45 strike highlighted in orange:
For the various different available expirations for AMGN options, ISRG options, or EXEL options, visit StockOptionsChannel.com.
Also see:
Funds Holding DI
Institutional Holders of FSM
Top Ten Hedge Funds Holding ASTE
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Monday Option Activity: AMGN, ISRG, EXEL

(RTTNews) - Amgen (AMGN) and AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE (tezepelumab-ekko) as an add-on maintenance treatment for inadequately controlled chronic rhinosinusitis with nasal polyps or CRSwNP in adults and pediatric patients aged 12 years and older. TEZSPIRE is now the first and only biologic approved for CRSwNP that targets thymic stromal lymphopoietin (TSLP).
The approval expands TEZSPIRE's indication to a second disease characterized by epithelial-driven inflammation.
CRSwNP affects approximately 320 million people globally. It is a complex inflammatory condition marked by persistent inflammation and benign polyp growths within the nasal cavity. Patients often suffer from airflow obstruction, nasal congestion, and a reduced sense of smell. For many, existing treatments—such as systemic and intranasal corticosteroids or repeated sinus surgeries—fail to provide lasting relief.
Regulatory applications for TEZSPIRE in CRSwNP are currently under review in Europe, China, Japan, and several other countries, based on data from the WAYPOINT trial.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Amgen And AstraZeneca's TEZSPIRE Approved For Epithelial-Driven Nasal Inflammation

For Immediate Release
Chicago, IL – October 17, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly LLY, Novo Nordisk NVO, Amgen AMGN and Viking Therapeutics VKTX.
Here are highlights from Thursday’s Analyst Blog:
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
Eli Lilly is a dominant player in the cardiometabolic space, all thanks to the encouraging uptake for its blockbuster GLP-1 drugs — Mounjaro (for type II diabetes [T2D]) and Zepbound (for obesity). Though both products have been on the market for a little over three years, they now account for more than half of the company’s topline. Investors will be most keen to know the sales numbers of these two drugs when Lilly reports third-quarter results on Oct. 30, before the opening bell.
Notably, Mounjaro is the market leader in new prescriptions within T2D incretin analogs, enjoying a market share of 50% in the United States. Zepbound also holds a leading market share in the anti-obesity market, with 75% of total patients taking Zepbound. This is mainly due to the improved supply of both drugs in the country as a result of ramped-up production. Sales of Mounjaro and Zepbound have also benefited from launches in new international markets.
We believe that deeper penetration in the U.S. market and increased uptake in international markets are likely to have driven the growth of both drugs in the third quarter of 2025. Our model estimates for Mounjaro and Zepbound sales are pegged at $5.33 billion and $3.46 billion, respectively, for the to-be-reported quarter.
Beyond cardiometabolic health, Lilly’s broader portfolio — including the oncology drug Verzenio and immunology drug Taltz — also continues to deliver steady growth. The company’s recently launched drugs, such as Omvoh and Ebglyss in immunology, Jaypirca in oncology and Kisunla in neuroscience, have all been contributing to top-line growth.
LLY’s Peers in the Obesity Space
According to research conducted by Goldman Sachs, the obesity market in the United States is expected to reach $100 billion by 2030. Eli Lilly and Novo Nordisk presently dominate this space.
Mounjaro and Zepbound directly compete with Novo Nordisk’s semaglutide medicines, Ozempic for diabetes and Wegovy for obesity. Like Lilly, Novo also generates a substantial portion of revenues from both drugs.
Several other companies, like Amgen and Viking Therapeutics, are also making rapid progress in the obesity space. Amgen has launched a broad phase III program for its dual GIPR/GLP-1 agonist, MariTide, targeting obesity and diabetes. Meanwhile, Viking Therapeutics is progressing two late-stage studies of its injectable VK2735 and reported mixed mid-stage data on the oral version in August, prompting a sharp stock decline.
LLY’s Price Performance, Valuation and Estimates
Shares of Lilly have outperformed the industry year to date.
From a valuation standpoint, Eli Lilly is expensive. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 28.29 times forward earnings, higher than its industry’s average of 15.60. However, the stock is trading below its five-year mean of 34.54.
The bottom-line estimate for 2025 has declined from $23.15 to $23.01 per share, while that for 2026 has fallen from $30.82 to $30.79 over the past 30 days.
Eli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Get all the details here >>
Zacks Investment Research
800-767-3771 ext. 9339
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics

In the latest close session, Amgen (AMGN) was up +1.18% at $297.32. The stock's performance was ahead of the S&P 500's daily gain of 0.4%. Meanwhile, the Dow lost 0.04%, and the Nasdaq, a tech-heavy index, added 0.66%.
Prior to today's trading, shares of the world's largest biotech drugmaker had gained 7.6% outpaced the Medical sector's gain of 1.8% and the S&P 500's gain of 1.02%.
Market participants will be closely following the financial results of Amgen in its upcoming release. The company plans to announce its earnings on November 4, 2025. The company is expected to report EPS of $5.03, down 9.86% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $8.94 billion, up 5.14% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $21.08 per share and revenue of $35.65 billion, indicating changes of +6.25% and +6.65%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Amgen should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.09% lower. Amgen is currently sporting a Zacks Rank of #3 (Hold).
In the context of valuation, Amgen is at present trading with a Forward P/E ratio of 13.94. For comparison, its industry has an average Forward P/E of 19.66, which means Amgen is trading at a discount to the group.
One should further note that AMGN currently holds a PEG ratio of 2.6. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. AMGN's industry had an average PEG ratio of 1.85 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 88, finds itself in the top 36% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amgen Inc. (AMGN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Amgen Inc.

Trend

Trend Class

Trend Power

Pattern

EMA

EMA-20

EMA-50

EMA-100

EMA-20

EMA-50

EMA-100

Oscillators

Stochastic

RSI

MACD

Candle pattern type